^
    Back
    Association details:
    Biomarker:ALK positive
    Cancer:Non-Hodgkin’s Lymphoma
    Drug:Xalkori (crizotinib) (ALK inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A1 - Approval
    Source:
    FDA
    Published date:
    01/14/2021
    Excerpt:
    XALKORI is a kinase inhibitor indicated for the treatment of…pediatric patients 1 year of age and older and young adults with relapsed or refractory, systemic anaplastic large cell lymphoma (ALCL) that is ALK-positive.
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Crizotinib Combined With Etoposide Capsule Followed by Auto-HSCT for Relapsed and Refractory ALK+ ALCL

    Excerpt:
    ...- patients with ALK-positive Anaplastic Large Cell Lymphoma diagnosed by immuno-histochemistry (IHC) or fluorescence in situ hybridization (FISH);...
    Trial ID:
    NCT03707847
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ASH 2021
    Title:

    ALK Inhibitor Plus Vinblasitine for Refractory/Relapsed Pediatric ALK+ Anaplastic Large Cell Lymphoma: A Prospective, One-Arm, Open-Label Real-World Study

    Published date:
    11/04/2021
    Excerpt:
    To assess the efficacy and safety of ALK inhibitors combined with VBL in pediatric relapsed/refractory (r/r) ALK+ ALCL....ALK inhibitors included crizotinib(CZ), alectinib(AL) and ceritinib(CER)....After 1st cycle of treatments, 62.9%(17/26) achieved comlpele remission(CR) without measurable tumors and ALK gene transcription, no progressed cases.... ALK inhibitors combined with VBL may rapidly induce the tumor remission of r/r ALK+ALCL and the tolerance is good.
    Secondary therapy:
    vinblastine
    DOI:
    10.1182/blood-2021-149402
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Am J Hematol
    Title:

    Long-term effects of crizotinib in ALK-positive tumors (excluding NSCLC): A phase 1b open-label study

    Published date:
    02/08/2018
    Excerpt:
    Our study cohorts show notable and durable antitumor activity of crizotinib as monotherapy for patients with advanced, relapsed or refractory ALK‐positive ALCL.... 
    DOI:
    10.1002/ajh.25043
    Trial ID:
    PROFILE 1013
    Evidence Level:
    Sensitive: C3 – Early Trials
    New
    Source:
    Lancet Oncol
    Title:

    Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study

    Excerpt:
    ...antitumour activity of crizotinib in children with refractory solid tumours and anaplastic large-cell lymphoma. Objective tumour responses were documented in 14 of 79 patients (nine complete responses, five partial responses); and the anti-tumour activity was enriched in patients with known activating ALK aberrations (eight of nine with anaplastic large-cell lymphoma, one of 11 with neuroblastoma, three of seven with inflammatory myofibroblastic tumour, and one of two with NSCLC).
    DOI:
    10.1016/S1470-2045(13)70095-0
    Trial ID:
    NCT00939770
    Evidence Level:
    Sensitive: C4 – Case Studies
    Source:
    Frontiers
    Title:

    Unusual Late Relapse of ALK-Positive Anaplastic Large Cell Lymphoma Successfully Cleared Using the ALK-Inhibitor Crizotinib: Case Report

    Published date:
    10/02/2020
    Excerpt:
    ...we present a patient with a rare late relapse of ALK-positive ALCL following anthracycline-based chemotherapy, who entered ongoing complete remission after initiation of treatment with crizotinib.
    DOI:
    10.3389/fonc.2020.585830
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    Cancers (Basel)
    Title:

    settings Open AccessArticle Synergistic Drug Combinations Prevent Resistance in ALK+ Anaplastic Large Cell Lymphoma

    Published date:
    09/01/2021
    Excerpt:
    Finally, to further validate the potentialities of this combined approach, we sought an in vivo proof of concept, employing a xenograft model of ALK+ ALCL. Combined therapy with crizotinib+decitabine or crizotinib+trametinib resulted in a significantly higher inhibition of tumor growth compared to single treatments, while tumors treated with crizotinib+CHO showed a trend toward better inhibition compared to single drugs.
    Secondary therapy:
    decitabine
    DOI:
    10.3390/cancers13174422
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    Cancers (Basel)
    Title:

    Synergistic Drug Combinations Prevent Resistance in ALK+ Anaplastic Large Cell Lymphoma

    Published date:
    09/01/2021
    Excerpt:
    Finally, to further validate the potentialities of this combined approach, we sought an in vivo proof of concept, employing a xenograft model of ALK+ ALCL. Combined therapy with crizotinib+decitabine or crizotinib+trametinib resulted in a significantly higher inhibition of tumor growth compared to single treatments, while tumors treated with crizotinib+CHO showed a trend toward better inhibition compared to single drugs.
    Secondary therapy:
    CHOP
    DOI:
    10.3390/cancers13174422